AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Shattuck Labs, Inc.
Video analysis: STTK
All videosNo video analysis for this stock yet. Request one from our team.
News: STTK
3,750,000 Shares in Shattuck Labs, Inc. $STTK Purchased by Frazier Life Sciences Management L.P.
Frazier Life Sciences Management L.P. bought a new position in shares of Shattuck Labs, Inc. (NASDAQ: STTK) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,750,000 shares of the company's stock, valued at approximately $26,025,000. Frazier Life Sciences Management L.P. owned 3.74%
BlackRock Inc. Invests $27.32 Million in Shattuck Labs, Inc. $STTK
BlackRock Inc. purchased a new stake in Shattuck Labs, Inc. (NASDAQ: STTK) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 3,935,810 shares of the company's stock, valued at approximately $27,315,000. BlackRock Inc. owned about 5.13% of Shattuck Labs as of its
Shattuck Labs Announces Participation in Upcoming September Investor Conferences
AUSTIN, Texas and DURHAM, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potential first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced that company management will present at and participate in the following upcoming investor conferences:
Shattuck Labs: A Receptor-Side Bet On The TL1A Boom
Shattuck Labs pivots to immunology, focusing on DR3-targeted therapies for IBD, notably SL-325, after discontinuing its oncology program. SL-325's Phase 1 data show strong safety, low immunogenicity (3.7% ADA rate), and durable receptor occupancy, supporting quarterly dosing potential. STTK is fully funded through Phase 2b efficacy readout, with cash runway into 2029 despite significant dilution; valuation trades at a forward price-to-book discount.
What Shattuck Labs Stock Topped the Market on Monday
One of them initiated coverage. The company has a very promising lead drug candidate.
Shattuck Labs, Inc. (STTK) is a Great Momentum Stock: Should You Buy?
Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Geron (NASDAQ:GERN) and Shattuck Labs (NASDAQ:STTK) Head to Head Comparison
Geron (NASDAQ: GERN - Get Free Report) and Shattuck Labs (NASDAQ: STTK - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Geron and
Wall Street Analysts Believe Shattuck Labs (STTK) Could Rally 85.31%: Here's is How to Trade
The consensus price target hints at an 85.3% upside potential for Shattuck Labs (STTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
